Swiss-based computational firm Genedata announces that its software system for analyzing high throughput screening data, Genedata Screener®, is in full operation at Chugai Pharmaceutical Co., Ltd. Scientists at Chugai use the system to support drug discovery efforts for disease areas such as oncology, and for diseases of the bone and joint.
During the past twelve months Genedata Screener has provided computational support throughout a complete screening cycle at Chugai.
Beginning with assay optimization and followed by primary and validation screening phases, Screener has enhanced Chugai’s search for active compounds with robust measures for biological effects within the screening cascade.
Genedata’s computational scientists in Japan, based in Tokyo, have integrated Genedata Screener® with research infrastructure at Chugai. It has been connected to Chugai’s screening platforms and result databases, providing data quality assurance and automating the analysis process from the plate readers all the way to the corporate databases.
Chugai’s screening experts use the AssayAnalyzer module to gain an overview of data quality for entire screening campaigns. Genedata’s Condoseo module is used to estimate the potency of compounds screened at multiple concentrations in the validation screening phase.